New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
05:55 EDTAMD, AMD, AMD, AMD, AMD, VAR, VAR, VAR, VAR, VAR, RDNT, RDNT, RDNT, RDNT, RDNT, PKI, PKI, PKI, PKI, PKI, NTAP, NTAP, NTAP, NTAP, NTAP, MDT, MDT, MDT, MDT, MDT, HOLX, HOLX, HOLX, HOLX, HOLX, EMC, EMC, EMC, EMC, EMC, DELL, DELL, DELL, DELL, DELL, CERN, CERN, CERN, CERN, CERN, AWRE, AWRE, AWRE, AWRE, AWRE, ATHN, ATHN, ATHN, ATHN, ATHN, T, T, T, T, T, VMW, VMW, VMW, VMW, VMWRadiological Society of North America hosts a conference
RSNA 2012 is being held in Chicago on November 25-30.
News For AMD;T;ATHN;AWRE;CERN;DELL;EMC;HOLX;MDT;NTAP;PKI;RDNT;VAR;VMW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 21, 2014
15:35 EDTEMCNotable companies reporting before tomorrow's open
Subscribe for More Information
14:37 EDTEMCEMC October weekly 27.5 straddle priced for 4% move into Q3
Subscribe for More Information
14:34 EDTVMW, EMCEarnings Preview: EMC reports after HPQ merger talks said to end
EMC Corporation (EMC) is expected to report third quarter earnings before the bell on Wednesday, October 22, with a conference call scheduled for 8:30 am ET. EMC provides software, hardware and IT services to business customers through its three federated businesses: EMC Information Infrastructure, Pivotal and VMware Virtual Infrastructure, which is represented by EMCís majority equity stake in VMware (VMW). VMware is expected to report on its own third quarter results after the bell on Tuesday, October 21, with a conference call scheduled for 5:00 pm ET. EXPECTATIONS: For EMC, analysts are looking for earnings per share of 46c on revenue of $6.0B. The consensus range is 44c-49c for EPS and $5.91B-$6.16B for revenue, according to First Call. Along with its last earnings report, EMC raised its FY14 adjusted EPS view to $1.91 from $1.90 and guided to FY14 revenues of $24.58B. Analysts consensus for FY14 EPS and revenue currently stand at $1.91 and $24.55B. For VMware, analysts are looking for earnings per share of 83c on revenue of $1.5B. The consensus range is 81c-85c for EPS and $1.48B-$1.52B for revenue, according to First Call. LAST QUARTER: EMC reported Q2 adjusted EPS of 43c, which matched the consensus expectation. EMC's revenue of $5.9B came in slightly ahead of the $5.83B consensus projection. EMC also accelerated its 2014 share buyback plan, stating that it now expects to repurchase an aggregate of $3B of the company's common stock in 2014. VMware reported Q2 EPS of 81c, versus consensus of 79c, on revenue $1.46B, versus consensus of $1.44B. NEWS: VMware held its "VMWorld 2014" conference from August 24-28, during which the company updated its 2015 guidance. VMware's guidance for revenue growth in the mid teens percentage level and margin expansion of up to one percentage point is positive, RBC Capital analyst Matthew Hedberg wrote in a note to investors on August 26. The same day Cowen analyst Gregg Moskowitz wrote that VMware's FY15 revenue guidance would "likely weigh modestly" on the stock, even though he was not surprised by the outlook. Less than two weeks ago, Elliott Management sent a letter to the board of directors of EMC Corporation detailing its recommendations on the right path forward for EMC, in which Elliott holds a stake. Elliott believes that EMCís Federation structure obscures enormous value at the company and that the board and management should pursue pathways to recognize this value, including a separation of VMware from Core EMC and/or various M&A opportunities, Elliott wrote. In response, EMC said its directors regularly review and evaluate the company's strategy with a view towards enhancing shareholder value. "Over the past few months, EMC's leadership has met with representatives of Elliott several times and has listened carefully to their ideas, as we do with all of our shareholders," the company said. Last week, HP (HPQ) announced the resumption of its share repurchase program after Reuters reported the company's merger talks with EMC had ended. HP had suspended the buyback program due to "possession of material non-public information." The tech giant said that day that it is "no longer in possession of such information." During September, Re/code reported, citing sources familiar with Oracle's plans, that the company was not interested in acquiring EMC. Meanwhile, Cisco (CSCO) CEO John Chambers also said last month at a Wall Street Journal breakfast that his company is not among the potential merger partners for EMC. Chambers said a deal between the two companies would have been done a "year or two ago" were it to happen, according to Reuters. STREET RESEARCH: On the day after its last earnings report, Brean Capital raised its price target on EMC to $33 from $30, citing the company's aggressive capital return strategy, encouraging core Storage dynamics and potential pent up demand. Tigress Financial, however, downgraded EMC to Buy from Strong Buy, citing valuation. Additionally, VMware estimated that its total available market would reach more than $60B in 2017, versus its estimate last year of a $50B+ total addressable market by 2016, Moskowitz noted. PRICE ACTION: In afternoon trading, EMC shares are up 1% to $27.22, while VMware is fractionally higher at $87.79. Over the last three months, EMC shares have declined almost 4%, while VMware's stock is down about 5.5% in that same time frame.
13:30 EDTVMWVMware October weekly 88 straddle priced for 7.2% move into Q3
Subscribe for More Information
13:09 EDTTEarnings Preview: AT&T to benefit from strong iPhone 6 demand, Wells Fargo says
AT&T (T) is expected to report third quarter earnings after the market close on Wednesday, October 22, with a conference call scheduled for 4:30 pm ET. AT&T is a global telecommunications company offering wireless and long distance services. EXPECTATIONS: Analysts are looking for earnings per share of 64c on revenue of $33.24B, according to First Call. The consensus range for EPS is 59c-66c on revenue of $31.77B-$34.34B. LAST QUARTER: AT&T reported second quarter EPS of 62c against estimates for 63c on revenue of $32.6B against estimates for $33.22B. On its Q2 earnings report, the company forecast FY14 EPS growth at the low end of a mid-single digit range, compared to consensus of $2.62. It sees: FY14 consolidated revenue growth in the 5% range, versus consensus $133.93B; FY14 free cash flow in the $11B range; FY14 capital expenditures remaining in the $21B range. In Q2, AT&T reported the following: total branded smartphone net adds, both postpaid and prepaid, of 576,000; total branded tablet net adds of 250,000; 366,000 postpaid tablet net adds; postpaid churn of 0.86%. On September 25, DirecTV (DTV) stockholders voted overwhelmingly to approve DIRECTVís proposed merger with AT&T. STREET RESEARCH: Street research has been light in the weeks leading up to AT&T's Q3 earnings report. On September 15, Wells Fargo said AT&T should particularly benefit from strong Apple (AAPL) iPhone 6 demand. After Apple reported that over 4M iPhone 6 units were pre-ordered in the first 24 hours of eligibility, Wells Fargo said that it believed strong demand for the phones will be positive for all of the wireless carriers, but particularly for AT&T because of its strategic decision to focus on its early upgrade "Next!" program. The firm maintained its Outperform rating on AT&T. PRICE ACTION: AT&Tís shares have fallen approximately 4% since the company's Q2 report, but they did manage to make a 52-week high of $37.48 in late July. In afternoon trading ahead of tomorrowís Q3 report, AT&Tís shares are up 0.5%.
12:08 EDTATHNEinhorn says athenahealth 'doesn't earn any money'
Subscribe for More Information
12:06 EDTATHNEinhorn says short thesis on athenahealth 'working itself out'
Subscribe for More Information
10:00 EDTPKIOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AbbVie (ABBV) downgraded to Neutral from Buy at Guggenheim... BHP Billiton (BHP) downgraded to Hold from Buy at Jefferies... Bank of Marin (BMRC) downgraded to Market Perform from Outperform at Keefe Bruyette... Cobalt (CIE) downgraded to Speculative Buy from Buy at Global Hunter... Consolidated Edison (ED) downgraded to Underweight at Morgan Stanley... Deutsche Post (DPSGY) downgraded to Hold from Buy at Deutsche Bank... HCP (HCP) downgraded to Hold from Buy at Jefferies... IBM (IBM) downgraded to Hold from Buy at Evercore... Inland Real Estate (IRC) downgraded to Underperform from Neutral at BofA/Merrill... PerkinElmer (PKI) downgraded to Neutral from Buy at Janney Capital... Philips (PHG) downgraded to Neutral at UBS... QEP Midstream Partners (QEPM) downgraded to Market Perform at Wells Fargo... Rent-A-Center (RCII) downgraded to Market Perform from Outperform at Raymond James... Rhino Resources (RNO) downgraded to Underperform from Market Perform at Raymond James... Universal Forest (UFPI) downgraded to Neutral from Buy at Sterne Agee.
09:52 EDTMDTCovidien rises after Medtronic maintains merger date language
Shares of Covidien (COV) are rising in early trading after Medtronic (MDT), in its latest regulatory filing answering questions for shareholders regarding its proposed takeover of the Irish drugmaker, left its language regarding the expected closing date unchanged. WHAT'S NEW: In its most recent filing, Medtronic again stated, "As of the date of this joint proxy statement/prospectus, the transaction is expected to be completed late in the fourth calendar quarter of 2014 or early 2015. However, no assurance can be provided as to when or if the transaction will be completed. The required vote of Medtronic and Covidien shareholders to adopt the required shareholder proposals at their respective special meetings, as well as the necessary regulatory consents and approvals, must first be obtained and other conditions specified in the conditions appendix must be satisfied or, to the extent applicable, waived." ANALYST REACTION: Research firm BTIG says Medtronic's amended regulatory filing on the Covidien transaction increases the firm's confidence of the deal closing by early 2015. The firm adds it would be "stunned" to see Medtronic walk away from the merger after the company again showed commitment to the acquisition. WHAT'S NOTABLE: AbbVie (ABBV) last night confirmed that the company and Shire (SHPG), another Irish domiciled drugmaker, agreed to terminate their proposed merger. AbbVie said its decision was based upon its assessment of the September 22 notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in a "uniquely selective manner designed specifically to destroy the financial benefits of these types of transactions." AbbVie continued that the Treasury notice "introduced an unacceptable level of risk and uncertainty given the magnitude of the proposed changes" and the stated intention of the department to continue to revise tax principles to further impact such "tax inversion" transactions. AbbVie noted that it has agreed to pay Shire a break fee of approximately $1.64B due to the deal falling through. PRICE ACTION: In early trading, shares of Covidien trading in New York rose 4% to $88.86, Medtronic advanced 1% to $64.57, Shires gained 0.7% to $185.82 and AbbVie added 1.4% to $55.16.
09:43 EDTMDTAmended filing increases confidence in Covidien deal at BTIG
BTIG says Medtronic's (MDT) amended regulatory filing on the Covidien (COV) transaction increases its confidence of the deal closing by early 2015. The firm adds it would be "stunned" to see Medtronic walk away from the merger after the company again showed commitment to the acquisition. Shares of Covidien are up 3% to $88.11 in early trading.
09:11 EDTMDTMedtronic keeps language unchanged on merger closing date
Medtronic in its latest regulatory filing answering questions for shareholders regarding its proposed takeover of Covidien (COV) left the language unchanged around the expected closing date. The company again stated, "As of the date of this joint proxy statement/prospectus, the transaction is expected to be completed late in the fourth calendar quarter of 2014 or early 2015. However, no assurance can be provided as to when or if the transaction will be completed. The required vote of Medtronic and Covidien shareholders to adopt the required shareholder proposals at their respective special meetings, as well as the necessary regulatory consents and approvals, must first be obtained and other conditions specified in the conditions appendix must be satisfied or, to the extent applicable, waived."
08:02 EDTPKIPerkinElmer downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information
October 20, 2014
09:59 EDTEMCEMC weekly volatility elevated into Q3 and outlook
EMC October weekly call option implied volatility is at 52, November is at 29, December is at 26, January is at 25; compared to its 26-week average of 21 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on October 22.
07:20 EDTMDTInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
07:15 EDTTAT&T weekly volatility elevated into Q3 and outlook
Subscribe for More Information
07:15 EDTAWREAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:12 EDTMDT, VARCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTHOLXAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPKIAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
06:38 EDTATHNathenahealth price target lowered to $115 from $140 at RBC Capital
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use